Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency

Cancer Investigation

Volumn 17, Issue 3, 1999, Pages 201-205

  Shehata, Nadine ^a   Pater, Alan ^b   Tang, Shou Ching ^a,b,c  

^a Newfoundland Cancer Treatm Res F   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c Dr H Bliss Murphy Cancer Center   (Canada)

Author keywords

5 Fluorouracil; Colon cancer chemotherapy; Dihydropyrimidine dehydrogenase deficiency; Neurotoxicity

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; COLON CANCER; COMORBIDITY; DERMATITIS; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; ENZYME DEFICIENCY; HUMAN; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; PRIORITY JOURNAL;

EID: 0033036589     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909021422     Document Type: Article

References (24)

1. Milano G, Etienne M-C: Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anti-cancer Res 14:2295-2298, 1994.
2. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993.
3. Sommadossi J-P, Gerwirtz DA, Diasio RB, et al: Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 257:8171-8176, 1982.
4. Fleming R, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992.
5. Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249, 1985.
6. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 81:47-51, 1988.
7. Riebl J-L, Brown WJ: Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 961-967, 1964.
8. Lynch HT, Droszcz CP, Albano WA, et al: "Organic brain syndrome" secondary to 5-fluorouracil toxicity. Dis Colon Rectum 24:130-131, 1981.
9. Hook CC, Kimmel DW, Kvols LK, et al: Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neural 31:262-267, 1992.
10. Fassas AB-T, Gattani AM, Morgello S: Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest 12:379-383, 1994.
11. Takimoto CH, Lu Z, Zhang R, et al: Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2:477-481, 1996.
12. Fleming RA, Milano GA, Gaspard MH, et al: Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29A:740-744, 1993.
13. Bourke RS, West CR, Chheda G, et al: Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 33:1735-1746, 1973.
14. Stephan F, Etienne M-C, Wallahs C, et al: Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 99:685-688, 1995.
15. Chainage H, Panel A: Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy. Trans Am Neurol Assoc 94:290-292, 1969.
16. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68:499-501, 1991.
17. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253, 1994.
18. Milano G, Etienne M-C: Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogen 4:301-306, 1994.
19. Daher GC, Naquib FN, el-Kouni MH, et al: Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. Biochem Pharmacol 41:1887-1893, 1991.
20. Spector T, Cao S, Rustum YM, et al: Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 55:1239-1241, 1995.
21. Baccanari DP, Davis ST, Knick VC, et al: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90: 11064-11068, 1993.
22. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994.
23. Rowinsky EK, Baker SD: The dihydropyrimidine dehydrogenase inhibitor 776C85: making oral 5-fluorouracil practical and modifying its therapeutic index. Cancer Invest 15(Suppl 1):16-18, 1996.
24. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438.